Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4161594 | 0.87 | AKR1B1 (0.42) | SCN9AAKR1B1 | |
| SCHEMBL4168475 | 0.87 | ADAMTS5 (0.38) | SIRT2ALDH1A1MAPTALOX15TSHR | |
| SCHEMBL4254336 | 0.80 | ALDH1A1 (0.51) | SCN9AALDH1A1MAPTHSD17B10ALPL | |
| SCHEMBL10802626 | 0.80 | APAF1 (0.48) | SCN9AALDH1A1MAPTALOX15TSHR | |
| SCHEMBL4167879 | 0.78 | AKR1A1 (0.35) | ALDH1A1ALOX15TSHRHSD17B10KDM4E | |
| SCHEMBL10955719 | 0.77 | SCN9A (0.41) | SCN9AALDH1A1MAPTALOX15TSHR | |
| SCHEMBL4172070 | 0.76 | SCN9A (0.44) | SCN9AALDH1A1MAPTALPLITGA4 | |
| SCHEMBL10954920 | 0.75 | ALPL (0.41) | SCN9AALDH1A1ALPLITGA4AKR1B1 | |
| SCHEMBL4257897 | 0.75 | MAPT (0.40) | SCN9AALDH1A1MAPTHSD17B10ALPL | |
| SCHEMBL4169745 | 0.73 | TSHR (0.54) | ALDH1A1TSHRHSD17B10ITGA4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | SCN9A 176/4885SIRT2 1513/4885ALDH1A1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.